IGC Pharma, Inc. (IGC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

IGC Pharma, Inc. (IGC) closed at USD 0.25 on 2026-10-15, a change of -37.5 % over the past year, with a market capitalization of USD 25.43M.

IGC Pharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

IGC Pharma, Inc. key figures

Previous close

USD 0.25 (2026-10-15)

1-year change

-37.5 %

Market cap

USD 25.43M

Enterprise value

USD 26.16M

P/E ratio (trailing)

-3.51

P/E ratio (forward)

-3.08

EPS (trailing)

-0.07

EPS (forward)

-0.08

PEG ratio

n/a

Price to book

4.10

Revenue growth

-19.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.58

Employees

70

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for IGC Pharma, Inc. and compare it with other stocks.